Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

(MedPage Today) — CHICAGO — Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115842

Author :

Publish date : 2025-06-01 21:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Tumor Treating Fields Boost Pancreatic Cancer Survival

Related Posts

Biomarker sNfL Falls Short for MS Diagnosis, Experts Say

Patients With HS, Obesity Report Improvements With GLP-1 RAs

Greater awareness not more cases behind ADHD surge, study suggests

First bacteria we meet can keep us out of hospital

Pregnant women warned against using weight-loss jabs

Is ADHD on the rise? No – but that answer doesn’t tell the whole story

Biomarker sNfL Falls Short for MS Diagnosis, Experts Say

Patients With HS, Obesity Report Improvements With GLP-1 RAs

Greater awareness not more cases behind ADHD surge, study suggests

First bacteria we meet can keep us out of hospital

Pregnant women warned against using weight-loss jabs

Is ADHD on the rise? No – but that answer doesn’t tell the whole story

SGLT2 Inhibitor Shows Promise as MASH Treatment

HELP Committee Supports Reauthorizing FDA Program to Streamline Review of OTC Drugs

Categories

Archives